Merck & Co.
Search results
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases.
Pfizer Canada strives to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines. Our diverse portfolio offers a broad range of benefits and solutions to meet the needs of Canadians.
Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
KIRKLAND, QC, April 23, 2021 — Pfizer Canada today announced it has reached an agreement with the Government of Canada to supply up to 125 million doses of the Pfizer-BioNTech COVID-19 vaccine in 2022 and 2023, with options to supply up to 60 million additional doses in 2024.
The Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine is approved for people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months has not yet been established.
Dec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted FDA approval. Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose. More than 1.2 billion Pfizer-BioNTech doses have been delivered to more than 120 countries or territories around the world since December 2020.
Pfizer Canada is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. We strive to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines.
Help protect yourself with the latest Pfizer-BioNTech. COVID-19 vaccine, COMIRNATY Omicron XBB.1.5. The Pfizer-BioNTech vaccines are helping protect Canadians against Covid-19. When it’s time for your next dose, ask your healthcare provider about our latest COVID-19 vaccine available, COMIRNATY Omicron XBB.1.5.
Jun 25, 2022 · Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response ...
Oct 7, 2022 · Health Canada has approved Pfizer's new bivalent COVID-19 vaccine that contains mRNA from both the original SARS-CoV-2 virus and the Omicron BA.4 and BA.5 variants.
